全文增加细节
路透社3月5日 - 华尔街日报》周三援引知情人士的话报道称，生物技术公司Halozyme Therapeutics HALO.O认为默克公司的MRK.N抗癌大片Keytruda的新版本侵犯了其专利。
报道称，根据Halozyme的说法，默克公司必须签署一份许可协议才能销售其新版本。
默克公司正在开发Keytruda的注射版本，当静脉注射版本在本十年晚些时候失去专有权时，该版本可以保护其免受竞争。
默克公司和Halozyme公司没有立即回应路透社的置评请求。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.